The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review


Synonyms: Certican, Zortress, Votubia, Everolimus, everolimusum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Certican


Associations of Certican with other chemical compounds

  • This manuscript will review the preclinical rationale for undertaking a study of erlotinib combined with everolimus for patients with relapsed NSCLC [4].
  • In the sensitive cells, RAD001 showed a strong additive effect to the proapoptotic action of the chemotherapeutic agent etoposide [5].


  1. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Mabuchi, S., Altomare, D.A., Cheung, M., Zhang, L., Poulikakos, P.I., Hensley, H.H., Schilder, R.J., Ozols, R.F., Testa, J.R. Clin. Cancer Res. (2007) [Pubmed]
  2. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. Roccaro, A.M., Sacco, A., Jia, X., Banwait, R., Maiso, P., Azab, F., Flores, L., Manier, S., Azab, A.K., Ghobrial, I.M. Clin. Cancer Res. (2012) [Pubmed]
  3. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Daver, N., Boumber, Y., Kantarjian, H., Ravandi, F., Cortes, J., Rytting, M.E., Kawedia, J.D., Basnett, J., Culotta, K.S., Zeng, Z., Lu, H., Richie, M.A., Garris, R., Xiao, L., Liu, W., Baggerly, K.A., Jabbour, E., O'Brien, S., Burger, J., Bendall, L.J., Thomas, D., Konopleva, M. Clin. Cancer Res. (2015) [Pubmed]
  4. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Johnson, B.E., Jackman, D., Jänne, P.A. Clin. Cancer Res. (2007) [Pubmed]
  5. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Marinov, M., Ziogas, A., Pardo, O.E., Tan, L.T., Dhillon, T., Mauri, F.A., Lane, H.A., Lemoine, N.R., Zangemeister-Wittke, U., Seckl, M.J., Arcaro, A. Clin. Cancer Res. (2009) [Pubmed]
WikiGenes - Universities